Jack Bendheim Sells 1,235 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 1,235 shares of Phibro Animal Health stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $40.55, for a total value of $50,079.25. Following the completion of the sale, the chief executive officer directly owned 15,445 shares in the company, valued at approximately $626,294.75. This represents a 7.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total transaction of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.68, for a total value of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total value of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.16, for a total value of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total value of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total value of $141,011.20.

Phibro Animal Health Stock Up 0.1%

NASDAQ PAHC traded up $0.04 during trading hours on Tuesday, hitting $39.52. The company’s stock had a trading volume of 95,621 shares, compared to its average volume of 194,254. The company has a market capitalization of $1.60 billion, a PE ratio of 23.81, a price-to-earnings-growth ratio of 1.10 and a beta of 0.79. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $46.42. The company’s 50-day simple moving average is $40.05 and its two-hundred day simple moving average is $37.63. The company has a current ratio of 3.09, a quick ratio of 1.35 and a debt-to-equity ratio of 2.32.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. The firm had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Research analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were issued a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, November 26th. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. Phibro Animal Health’s payout ratio is presently 28.92%.

Hedge Funds Weigh In On Phibro Animal Health

A number of institutional investors have recently bought and sold shares of PAHC. Capricorn Fund Managers Ltd acquired a new stake in Phibro Animal Health in the 3rd quarter valued at approximately $10,233,000. JPMorgan Chase & Co. lifted its position in Phibro Animal Health by 1,730.9% in the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock valued at $9,634,000 after acquiring an additional 225,110 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Phibro Animal Health during the third quarter worth approximately $8,931,000. Ranger Investment Management L.P. increased its position in Phibro Animal Health by 101.1% in the 2nd quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock valued at $9,143,000 after acquiring an additional 179,975 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after acquiring an additional 154,281 shares during the period. 99.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PAHC. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. JPMorgan Chase & Co. upped their price target on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Phibro Animal Health has a consensus rating of “Hold” and an average price target of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.